MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

Official Title: “A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control”

A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.

Intervention(s) in this Clinical Trial

• Drug: Sitagliptin phosphate
  • Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
• Drug: Pioglitazone hydrochloride
  • Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
• Drug: Matching placebo to sitagliptin
  • Matching placebo to sitagliptin orally once daily for 54 weeks.
• Drug: Matching placebo to pioglitazone
  • Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
• Drug: Metformin
  • Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: Sitagliptin 100 mg
• Experimental: Pioglitazone 15 mg
• Experimental: Pioglitazone 30 mg
• Experimental: Pioglitazone 45 mg
• Experimental: Sitagliptin 100 mg/ Pioglitazone 15 mg
• Experimental: Sitagliptin 100 mg/ Pioglitazone 30 mg
• Experimental: Sitagliptin 100 mg/ Pioglitazone 45 mg

Primary Measures

• Change From Baseline in Hemoglobin A1C (A1C) at Week 24
  • Time Frame: Baseline and Week 24
    Safety Issue?: No
• Change From Baseline in A1C at Week 54
  • Time Frame: Baseline and Week 54
    Safety Issue?: No

Secondary Measures

• Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
  • Time Frame: Baseline and Week 24
    Safety Issue?: No
• Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 24
  • Time Frame: Baseline and Week 24
    Safety Issue?: No
• Change From Baseline in FPG at Week 54
  • Time Frame: Baseline and Week 54
    Safety Issue?: No
• Change From Baseline in 2-Hour PMG at Week 54
  • Time Frame: Baseline and Week 54
    Safety Issue?: No

Inclusion Criteria:

• Patient is highly unlikely to conceive
• Patient meets one of the 3 categories is naïve to all antihyperglycemic agent (AHA) therapies, or is non-naïve based upon the patient's current diet, medical regimen and screening A1c patient is currently not on AHA with a screening A1c >=7.5 % and =<11.0
• % patient is currently on either metformin pr sulfonylurea monotherapy with a screening A1c >=7.0 % and =<9.0 %

Exclusion Criteria

• Patient has a history of type 1 diabetes mellitus or history of ketoacidosis or has
• C=peptide value of =<0.8 ng/mL
• Patient has previously been treated with insulin, thiazolidinedione (TZD) (rosiglitazone or pioglitazone), any Dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin, vildagliptin, or alogliptin), exenatide or has previously been in a clinical study with any DPP-4 inhibitor or incretin mimetic
• Patient is on a weight loss program and is not in the maintenance phase or has started a weight loss medication (e.g. orlistat or sibutramine) within the prior 8 weeks
• Patient has undergone surgery within the prior 30 days or has major surgery planned during the study
• Patient has a medical history of active liver disease including chronic active hepatitis B or C or symptomatic gallbladder disease including primary biliary cirrhosis
• Patient has received treatment with an investigational product within 12 weeks prior to Visit 1

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 78 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Merck Industry

Information obtained from ClinicalTrials.gov on February 09, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00722371

Study ID Number: MK-0431-102

ClinicalTrials.gov Identifier: NCT00722371

Health Authority: United States: Food and Drug Administration